Siegel, R. L., Miller, Ok. D., Fuchs, H. E. & Jemal, A. Most cancers statistics, 2022. CA Most cancers J. Clin. 72, 7–33. https://doi.org/10.3322/caac.21708 (2022).
Li, Y., Wang, Y., Wang, Z., Yi, D. & Ma, S. Racial variations in three main NHL subtypes: Descriptive epidemiology. Most cancers Epidemiol. 39, 8–13 (2015).
Scarfò, L., Ferreri, A. J. & Ghia, P. Power lymphocytic leukaemia. Crit. Rev. Oncol. Hematol. 104, 169–182 (2016).
Kajüter, H. et al. Survival of sufferers with power lymphocytic leukemia earlier than and after the introduction of chemoimmunotherapy in Germany. Blood Most cancers J. 11, 1–4. https://doi.org/10.1038/s41408-021-00556-7 (2021).
Barnes, J. I. et al. Value-effectiveness of ibrutinib as first-line remedy for power lymphocytic leukemia in older adults with out deletion 17p. Blood Adv. 2, 1946–1956 (2018).
Shanafelt, T. D. et al. Impression of ibrutinib and idelalisib on the pharmaceutical value of treating power lymphocytic leukemia on the particular person and societal ranges. J. Oncol. Pract. 11, 252–258 (2015).
CADTH Reimbursement Overview Provisional Funding Algorithm for Power Lymphocytic Leukemia. (2021).
Burger, J. A. Remedy of power lymphocytic leukemia. N. Engl. J. Med. 383, 460–473. https://doi.org/10.1056/NEJMra1908213 (2020).
Kater, A. P. et al. Venetoclax plus rituximab in relapsed power lymphocytic leukemia: 4-year outcomes and analysis of impression of genomic complexity and gene mutations from the MURANO part III examine. J. Clin. Oncol. 38, 4042–4054. https://doi.org/10.1200/JCO.20.00948 (2020).
Al-Sawaf, O. et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for beforehand untreated power lymphocytic leukaemia (CLL14): Comply with-up outcomes from a multicentre, open-label, randomised, part 3 trial. Lancet Oncol. 21, 1188–1200. https://doi.org/10.1016/S1470-2045(20)30443-5 (2020).
Ghia, P. et al. ASCEND: Part III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory power lymphocytic leukemia. J. Clin. Oncol. 38, 2849–2861. https://doi.org/10.1200/JCO.19.03355 (2020).
Sharman, J. P. et al. Acalabrutinib with or with out obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive power lymphocytic leukaemia (ELEVATE-TN): A randomised, managed, part 3 trial. Lancet 395, 1278–1291. https://doi.org/10.1016/S0140-6736(20)30262-2 (2020).
Davids, M. S. et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline therapy for power lymphocytic leukaemia: A single-arm, open-label, part 2 examine. Lancet Oncol. 22, 1391–1402 (2021).
Ghia, P. et al. ASCEND: Part III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory power lymphocytic leukemia. J. Clin. Oncol. 38, 2849–2861 (2020).
Sheng, Z. et al. Comparability of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: A community meta-analysis. Leukemia Lymphoma 61, 3432–3439 (2020).
Remaining Suggestion for Acalabrutinib (Calquence) for Beforehand Untreated Power Lymphocytic Leukemia. (Canadian Company for Medication and Applied sciences in Well being, 2021).
Munir, T., Gaitonde, P. & Waweru, C. Value-effectiveness of acalabrutinib monotherapy in contrast with chlorambucil plus obinutuzumab for beforehand untreated power lymphocytic leukemia. Blood 136, 13–14 (2020).
Alrawashdh, N. et al. Value-effectiveness and financial burden analyses on all first-line therapies of power lymphocytic leukemia. Worth Well being 25, 1685–1695 (2022).
Gribben, J. G. The molecular biology of power lymphocytic leukemia. In Molecular Hematology, 111–120 (2019).
Hallek, M. & Al-Sawaf, O. Power lymphocytic leukemia: 2022 replace on diagnostic and therapeutic procedures. Am. J. Hematol. 96, 1679–1705 (2021).
Group, I. C.-I. W. A world prognostic index for sufferers with power lymphocytic leukaemia (CLL-IPI): A meta-analysis of particular person affected person knowledge. Lancet Oncol. 17, 779–790 (2016).
Burger, J. A. et al. Lengthy-term efficacy and security of first-line ibrutinib therapy for sufferers with CLL/SLL: 5 years of follow-up from the part 3 RESONATE-2 examine. Leukemia 34, 787–798. https://doi.org/10.1038/s41375-019-0602-x (2020).
Taylor, J., Xiao, W. & Abdel-Wahab, O. Analysis and classification of hematologic malignancies on the idea of genetics. Blood 130, 410–423. https://doi.org/10.1182/blood-2017-02-734541 (2017).
Knisbacher, B. A. et al. Molecular map of power lymphocytic leukemia and its impression on consequence. Nat. Genet. 54, 1664–1674 (2022).
Pointers for the Financial Analysis of Well being Applied sciences in Canada. (Canadian Company for Medication and Applied sciences in Well being, 2017).
Chan, B. Edamame. Model 1.0.0. , https://github.com/BrandonCChan/edamame (2022).
Al-Sawaf, O. et al. Fast enchancment of patient-reported outcomes with venetoclax plus obinutuzumab in sufferers with beforehand untreated CLL and coexisting circumstances: A potential evaluation from the CLL14 trial. Blood 134, 4305–4305. https://doi.org/10.1182/blood-2019-126542 (2019).
Sharman, J. P. et al. Remaining outcomes of a randomized, part III examine of rituximab with or with out idelalisib adopted by open-label idelalisib in sufferers with relapsed power lymphocytic leukemia. J. Clin. Oncol. 37, 1391–1402. https://doi.org/10.1200/JCO.18.01460 (2019).
Seymour, J. F. et al. Venetoclax-rituximab in relapsed or refractory power lymphocytic leukemia. N. Engl. J. Med. 378, 1107–1120. https://doi.org/10.1056/NEJMoa1713976 (2018).
Beusterien, Ok. M. et al. RPeoseaprcuh lation choice values for therapy outcomes in power lymphocytic leukaemia: A cross-sectional utility examine. 9 (2010).
Mittmann, N. et al. Well being system prices for most cancers medicines and radiation therapy in Ontario for the 4 commonest cancers: A retrospective cohort examine. Can. Med. Assoc. Open Entry J. 8, E191–E198 (2020).
Younes, A. et al. Randomized part III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal middle B-cell diffuse giant B-cell lymphoma. J. Clin. Oncol. 37, 1285–1295. https://doi.org/10.1200/JCO.18.02403 (2019).
Regier, D. A. et al. Value-effectiveness of molecularly guided therapy in diffuse giant B-cell lymphoma (DLBCL) in sufferers beneath 60. Cancers 14, 908 (2022).
Calvente, L. et al. Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma. Br. J. Haematol. 190, 864–868. https://doi.org/10.1111/bjh.16777 (2020).
Alrawashdh, N., McBride, A. & Abraham, I. Value-effectiveness analyses of first line ibrutinib versus acalabrutinib versus zanubrutinib adopted by second line venetoclax plus rituximab in beforehand untreated power lymphocytic leukemia (CLL) sufferers. Blood 140, 2155–2156 (2022).
Chatterjee, A. et al. A Probabilistic cost-effectiveness evaluation of venetoclax and obinutuzumab as a first-line remedy in power lymphocytic leukemia in Canada. PharmacoEconomics-Open, 1–18 (2022).
Kim, M. S. & Prasad, V. Entrance-line CLL: The function of chemoimmunotherapy. Am. J. Hematol. 98(4), 560–561 (2023).
Sharman, J. P. et al. Efficacy and security in a 4-year follow-up of the ELEVATE-TN examine evaluating acalabrutinib with or with out obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve power lymphocytic leukemia. Leukemia 36, 1171–1175 (2022).
Gao, L., Nguyen, D. & Lee, P. A scientific evaluation of financial evaluations for the pharmaceutical therapy of power lymphocytic leukemia and acute myeloid leukemia. Professional Rev. Hematol. 15, 833–847 (2022).
